Swine respiratory disease affects the respiratory tract of swine. It is one of the prevalent cause of death in nursery pigs and grower/finisher pigs. There are multiple pathogens, viruses, and other secondary causative agents that causes respiratory disease in swine. Primary pathogens that causes swine respiratory disease include Actinobacillus pleuropneumoniae (APP), Mycoplasma hyopneumoniae, Bordetella bronchiseptica, and Pasteurella multocida. Viral agents involved includes porcine reproductive and respiratory syndrome (PRRS) virus and swine influenza virus (SIV). Various diseases that come under ambit of swine respiratory disease include mycoplasma pneumonia, swine influenza, classical swine fever atrophic rhinitis, pleuropneumonia, porcine reproductive, and respiratory syndrome, and porcine circovirus type 2. These infectious agents together increase the severity of the disease.
Get an exclusive sample copy of the business report: https://www.coherentmarketinsights.com/insight/request-sample/1274
China, the U.S., and E.U to drive growth of the swine respiratory disease treatment market due to high pork production
According to the factsheet by United Nations Food and Agriculture Organization (UN-FAO) worldwide, there is close to one billion headcount of swine. China has highest number of headcount, followed by the U.S. and EU. These regions are expected to drive growth of the respiratory disease treatment market, owing to high pork production. According to the United States Department of Agriculture (USDA), around 108.2 million metric tons of pork was produced in 2016, which requires supply of healthy swine. Early vaccination is essential for healthy swine as respiratory disease in swine leads to lung damage, poor growth of swine, medication cost, and in turn results into lower economic efficiency for swine farmer. Therefore many of these regions opt for vaccination to prevent the respiratory disease in swine, which in turn is expected to propel growth for the swine respiratory disease treatment market. According to the study published in Virology Journal in 2017, emergence of porcine cyclovirus type 3 in pigs in regions such as China, the U.S., and some part of Europe are expected to fuel growth of the swine respiratory disease treatment market. Moreover, according to the Scientific Reports published in 2013, porcine reproductive and respiratory syndrome is economically most important disease of swine in North America, Europe, and Asia Pacific. North America spends around US$ 600 million annually for treatment of the disease.
However, increasing inclination of population towards adoption of vegetarian diet in China leading to lower swine farming prospect is expected to hamper growth of the swine respiratory treatment market. Moreover, according to the United States Department of Agriculture (USDA) cost of pork was dropping till end of 2017, which negatively affected the swine farming.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1274
Swine Respiratory Disease Treatment Market Taxonomy:
On the basis of product type:
- Drugs
- Vaccines
On the basis of indication:
- Mycoplasmal Pneumonia
- Swine Influenza
- Classical Swine Fever
- Porcine Reproductive and Respiratory Syndrome (PRRS)
- Porcine Circovirus-associated Disease
- Pseudorabies
On the basis of distribution channel:
- Veterinary Hospital
- Pharmacies
Key players operating in the swine respiratory disease treatment market include Zoetis, Inc. Merck Animal Health, Bayer AG, Boehringer Ingelheim Vetmedica, Inc., Elanco Animal Health, Virbac Group, Norbrook, Ceva Santé Animale, Vetoquinol, Bimeda holdings PLC, and Agrilabs, Inc. In January 2018, FDA approved dose of 100 gram per ton feed for Lincomix (Product from Zoetis, Inc.), which contains lincomycin hydrochloride to reduce the severity of swine respiratory disease from Mycoplasma hyopneumoniae. Lincomix is the only feed medication approved against mycoplasma hyopneumoniae, which is leading cause for swine pneumonia. In 2016, Gamithromycin (ZACTRAN) was approved for use in pigs by USDA. In June 2017, a team of researchers from University of Leicester isolated 20 bacteriophages that targets 72 potential drug-resistant bacteria in pigs. This bacteriophages were found to be more specific for treatment of bacterial infections in pigs. MSD Animal Health (known as Merck Animal Health in the U.S. and Canada) in November 2017, signed an agreement to acquire Vilsan Pharmaceuticals which is a division of Vimar Group, based in Turkey. Vilsan Pharmaceuticals holds significant share in animal health products in Turkey.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
